Chetomin (52) exhibited antitumor activity in human myeloma cell lines and primary multiple myeloma cells from patients, suggestive of potential clinical value in multiple myeloma patients characterized by a high EP300 and HIF-1α expression [165]. Here, HIF1A is linked to plasma cell myeloma.